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Introduction
The Philadelphia-negative chronic myeloproliferative
neoplasms (Ph-negative MPNs) are classified by the
World Health Organization into polycythemia vera
(PV), essential thrombocythemia (ET), idiopathic
myelofibrosis (IMF), and chronic myeloid leukemia
together with rarer subtypes such as chronic neu-
trophilic leukemia, hypereosinophilic syndrome and
chronic eosinophilic leukemia.1 These disorders share
many features, such as hypercellularity of the marrow,
unstimulated overproduction of 1 or more lineages of
blood cells, increased risk of thrombosis and bleeding,
and they may spontaneously convert to acute leukemia,
and also to marrow fibrosis.2 These clonal hematopoietic
malignancies are considered to arise from transforma-
tion of pluripotent stem cells, and this leads to an
increased production of erythrocytes, leukocytes and/or
platelets.3,4 The pathogenesis of Ph-negative MPNs
has been investigated but has remained unclear. Several
studies have demonstrated a breakthrough finding by
detection of an activating mutation V617F in Janus
kinase 2 (JAK2) in some Ph-negative MPN patients.
This shed new light on the pathogenesis of Ph-negative
MPNs.5–8 This JAK2 V617F mutation was found in
70–90% of patients with PV, in 35–70% with ET, and
in 30–50% with IMF. Molecular and clinical evidence
has shown that the JAK2 V617F mutation has a
direct causal role in the pathogenesis of Ph-negative
MPNs.9,10
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MPL W515L/K mutations in Taiwanese MPN patients
The discovery of JAK2V617F has provided important
insight into the pathogenesis of PV, ET and IMF, but
the etiology of JAK2V617F-negative Ph-negative MPN
remains unknown. Recently, sequence analysis of the
erythropoietin receptor, thrombopoietin receptor and
granulocyte-colony stimulating factor receptor in JAK2-
negative PV, ET and IMF led to the discovery of a so-
matic tryptophan-to-leucine substitution mutation at
the transmembrane juxtamembrane junction of the
thrombopoietin receptor MPL (MPLW515L).11 In
addition, a small number of patients have an alternate
mutation at codon 515, which results in a tryptophan-
to-lysine substitution (MPLW515K).12 Expression of
MPLW515L in recipient mice results in a myeloprolifera-
tive disease with similarities to human IMF, including
reticulin fibrosis, megakaryocytic hyperplasia, spleno-
megaly, and extramedullary hematopoiesis. Similar to
JAK2V617F, MPLW515L is an acquired mutation that
induces cytokine-independent growth and thrombo-
poietin hypersensitivity, and results in constitutive
phosphorylation of JAK2, STAT3, STAT5, AKT, and
ERK. The frequency of the gain-of-function mutation
MPLW515K/L was reported to be 1% in ET and 5% in
IMF in the USA.12 Some patients may harbor coexisting
JAK2V617F and MPLW515K/L mutations.13,14 Although
MPLW515L/K mutations are much less common than
JAK2V617F, the detection of MPLW515L in MPN patients
may provide valuable information. We have determined
the frequency of the JAK2V617F mutation in Taiwanese
patients,15 but the frequency of MPLW515 mutations
has not yet been determined. Therefore, we conducted
this study to determine the prevalence of MPLW515K/L
mutations in Taiwanese patients with Ph-negative
MPN and myelodysplastic syndrome.
Methods
Genomic polymerase chain reaction (PCR)
This study was approved by the institutional ethics
committee of Taipei Veterans General Hospital,
Taiwan. Peripheral blood samples were collected from
a total of 110 patients and informed consent was
obtained from all patients.
Total DNA was isolated from leukocytes from
patients’ peripheral blood using a QIAamp DNA Mini
Kit (QIAGEN GmbH, Hilden, Germany) according
to the manufacturer’s instructions. The human MPL
exon 10 sequence was amplified from 0.5–1.0 μg of
genomic DNA by PCR using specific primers (forward
primer: 5 TGGGCCGAAGT CTGACCCTTT 3;
reverse primer: 5 ACAGAGCGAA CCAAGAATGC-
CTGT 3).10 The reaction was performed for 30 cycles
with a standard protocol and an annealing tempera-
ture of 60°C. The products were resolved on 2.5%
agarose gels and visualized by ethidium bromide stain-
ing. The specific band was purified and sequenced by
an ABI PRISM 3100 Genetic Analyzer (ABI Applied
Biosystems, Foster City, CA, USA).
Results
We extracted genomic DNA from the peripheral blood
of 105 patients. Of these patients, 88 were Ph-negative
MPN (Table 1) and 17 had myelodysplastic syndrome.
Diagnosis of ET, PV and IMF followed the criteria of
the Polycythemia Vera Study Group.16,17
After PCR amplification of the cytokine receptor
MPL exon 10 and subsequent sequencing, we found
Table 1. Characteristics of 88 patients with Philadelphia-negative chronic myeloproliferative neoplasms
Disease subtype
PV (n = 33) ET (n = 49) IMF (n = 6)
Sex (M/F) 22/11 27/22 5/1
Age (yr) 68 ± 13 67 ± 14 72 ± 16
Median disease duration (mo) 55 (14–273) 35 (10–180) 124 (70–264)
WBC (× 109/L) 12.1 ± 6.1 8.9 ± 4.8 8.9 ± 7.1
Hb (g/dL) 14.2 ± 2.1 12.6 ± 2.2 9.0 ± 1.8
Platelets (× 109/L) 442 ± 338 583 ± 227 56 ± 32
Erythropoietin 7.7 ± 3.3 15.5 ± 11.6 18.4 ± 12
BM fibrosis (+) 37.5% 40% 100%
Splenomegaly 55% 53% 100%
CAD or HT (+) 54.5% 42.9% 33.3%
JAK2 V617F (+) 28/33 (85%) 29/49 (59%) 2/6 (33%)
Thrombosis/hemorrhage 7/1 13/1 0/1
PV = polycythemia vera; ET = essential thrombocythemia; IMF = idiopathic myelofibrosis; WBC = white blood cell count; Hb = hemoglobin; BM = bone marrow;
CAD = coronary artery disease; HT = hypertension; JAK2 = Janus kinase 2.
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that all the patients showed a normal codon at 
allele 515.
Discussion
Our data showed that 88 patients with Ph-negative
MPN did not have MPLW515L/K mutations. Consis-
tent with our results, Hsiao et al also reported that
MPLW515L/K mutations could not be found in 53
Taiwanese patients with ET.18 Pardanani et al sug-
gested that MPLW515 mutations are disease-specific.12
In the USA, they are prevalent in 5–9% of patients
with IMF and in 1% of ET patients.11,12 Similarly, Hu
et al reported that 7% of American patients with IMF
showed these 2 mutations.19 However, we could not
detect MPLW515L/K mutations in 6 patients with IMF.
It appears that the genetic origins of IMF represent
the culmination of multiple genetic and possibly epige-
netic events. A number of laboratories have suggested
that additional genetic events might play a role in this
process.20–22 Comparative genomic hybridization stud-
ies have shown that gains of cytogenetic material occur
in more than 50% of patients with IMF and most com-
monly involve gains of 9p, 2q, 3p, chromosome 4, 12q
and 13q.22 Furthermore, Dingli et al have identified an
unbalanced translocation between chromosomes 1 and
6 with specific breakpoints (1,6) that they believe are
highly specific to IMF.20 These chromosomal sites may
harbor additional genes that play a role in the origins
of IMF. However, further studies with more patients
are needed to determine the incidence and role of
MPLW515L/K mutations in Taiwanese patients with IMF.
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